Drug intelligence / Profile preview

ferrous ascorbate + folic acid (Lifsa Pharma)

Development stage: Unknown
Lead developer: LIFSA Pharma
Modality: Small Molecules
Administration: Oral

Overview

Tulivite is an oral nutritional supplement developed by LIFSA Pharma, primarily indicated for the prevention and treatment of iron-deficiency anemia and folic acid deficiency. It typically contains a combination of ferrous ascorbate, a highly bioavailable form of iron, and folic acid (Vitamin B9). Iron is an essential component of hemoglobin, necessary for oxygen transport in the blood, while folic acid is crucial for DNA synthesis and red blood cell formation. This combination is frequently used during pregnancy to support maternal health and fetal development, helping to prevent neural tube defects and maternal anemia.

Brand names: Tulivite
Other names: iron + folic acidiron and folic acid

Targets

DNA

Beyond the preview

Go deeper on ferrous ascorbate + folic acid (Lifsa Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ferrous ascorbate + folic acid (Lifsa Pharma).

Explore the full profile